Glaucoma can progress silently even when you feel no change and your vision seems normal. Regular follow-up is not a formality. It is the only way to detect progression before it causes irreversible functional damage, says Dr Shibal Bhartiya.
Dr Shibal Bhartiya is a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. Her approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care. She is rated 5 stars across 1,500+ patient reviews on Google.
Why You Must Keep Every Glaucoma Appointment Even When You Feel Fine
Feeling fine is not the same as being stable. In glaucoma, these two things are completely disconnected. The disease destroys optic nerve fibres without pain, without blur, and without any signal that the patient can detect. A patient who feels perfectly well can be losing ground at every visit.
This is the central paradox of glaucoma management. The better your treatment is working, the more normal you feel. And the more normal you feel, the easier it is to believe follow-up is unnecessary. That belief is precisely what allows glaucoma to advance unchecked.
What Follow-Up Actually Detects
A glaucoma follow-up visit is not a routine check. It is a structured search for evidence of progression across multiple measurements taken over time.
Intraocular pressure trends. A single pressure reading tells your doctor your pressure at that moment. A series of readings across different times of day and different visits tells your doctor whether your pressure is consistently controlled, whether it spikes at certain times, and whether your current treatment is holding. Pressure that looks acceptable on a single reading can be inadequately controlled across the day. This only becomes visible across multiple visits.
Visual field progression. A single visual field test is a snapshot. Glaucoma progression is a movie. Your doctor needs at least three to five tests over time to establish a reliable baseline, and further tests beyond that to detect a meaningful trend. A single stable result does not confirm stability. It confirms only that one test, on one day, looked unchanged.
Optic nerve and nerve fibre layer imaging. Structural changes to the optic nerve often precede detectable functional field loss by months to years. Serial OCT imaging of the retinal nerve fibre layer and ganglion cell complex allows your doctor to see structural thinning before it translates into a measurable field defect. Missing visits means missing this early warning.
Treatment compliance and side effects. Follow-up is also when your doctor assesses whether you are using your drops correctly, whether you are tolerating them, and whether the treatment regimen remains appropriate for your lifestyle and disease stage. These conversations only happen at visits.
Glaucoma Progression Despite Treatment Is Common
One of the most important and least communicated facts in glaucoma care is that progression despite treatment occurs regularly. Studies consistently show that a significant proportion of treated glaucoma patients continue to lose visual field over time. Treatment reduces the rate of progression. It does not always stop it entirely.
This means that even a patient who is using drops every day without fail, attending every appointment, and doing everything correctly can still be losing ground. The purpose of follow-up in this context is to detect that progression early and adjust treatment before the loss becomes functionally significant.
A patient who stops attending follow-up because they feel stable removes the only mechanism available to catch this. By the time they notice something is wrong, the opportunity for early intervention has gone.
The Consequence of Missed Visits
Missing one appointment is not catastrophic. Missing a pattern of appointments is.
Glaucoma management depends on trends, not single data points. Progression is confirmed when a pattern of change appears across multiple tests. If visits are irregular, data points are missing. Trends cannot be identified. Progression is missed until it has advanced to a degree that cannot be explained away.
Patients who attend irregularly also lose the benefit of being compared against their own baseline. Your doctor needs your full longitudinal record to know whether a current test is better, worse, or the same as six months ago. Gaps in that record make interpretation unreliable.
The practical consequence is that a patient who attends every two years instead of every six months may present with moderate-to-advanced progression that could have been caught and managed at an earlier, more treatable stage.
When Glaucoma Changes Its Behaviour
Glaucoma is not a static disease. Its rate of progression changes over time and in response to factors that are not always within your control.
Age affects the optic nerve’s resilience. Blood pressure changes affect ocular perfusion. Systemic medications prescribed by other doctors can affect intraocular pressure. Seasonal variation in pressure has been documented. Psychological stress affects autonomic tone and may affect pressure regulation.
None of these changes produce symptoms. All of them can affect glaucoma behaviour. Follow-up is the mechanism by which your doctor detects these changes and responds to them. Without it, a shift in disease activity goes unrecognised until it has caused damage.
Remember This
| What Follow-Up Detects | Why It Cannot Be Self-Detected | Consequence of Missing It |
|---|---|---|
| IOP variation across time of day and seasons | Pressure fluctuation produces no symptoms | Inadequate control goes unrecognised |
| Visual field progression trend | Field loss is hidden by brain compensation | Progression confirmed only when advanced |
| Structural optic nerve thinning | Precedes functional loss, entirely silent | Early warning missed, intervention delayed |
| Treatment failure or tolerance issues | Drops may stop working without any sign | Inadequate treatment continues unchallenged |
| New systemic factors affecting pressure | Medications, blood pressure, age all shift disease | Unrecognised disease behaviour change |
How to Make Follow-Up Work in Real Life
Compliance with glaucoma follow-up is genuinely difficult. Appointments take time. Transport is a challenge for older patients. In a busy working life, a condition that produces no symptoms can feel like a low priority against competing demands.
These are real obstacles. They are also obstacles that cost vision when they are not addressed.
Practical steps that help include booking the next appointment before leaving the current one, setting calendar reminders six weeks before each due date, identifying a family member who understands the importance of follow-up and can support attendance, and informing your employer that glaucoma monitoring is a medical requirement, not an elective.
If transport is a barrier, teleconsultation for interim reviews between in-person visits is an option worth discussing with your doctor. Not all glaucoma assessments require physical attendance. Pressure checks and imaging require a clinic visit. Discussion of results, medication queries, and interim symptom review can often be handled remotely.
What to Tell Your Family
Glaucoma is a disease that families need to understand because patients often minimise it themselves. If your relative has glaucoma and is not attending follow-up because they feel well, the information in this article is for them and for you.
The disease your relative has can cause blindness. It does so silently. The appointments they are missing are the only mechanism by which that blindness is prevented. Feeling well is not evidence that the disease is not progressing. It is evidence that the disease is doing exactly what it always does, which is advancing without announcing itself.
Supporting follow-up attendance is one of the most concrete ways a family can protect a loved one’s long-term vision.
Frequently Asked Questions
How often do I need follow-up for glaucoma?
Frequency depends on disease severity, rate of progression, and how recently treatment was changed. Newly diagnosed patients and those with active progression typically need review every three to four months. Stable, well-controlled patients may be seen every six months. Annual visits are rarely sufficient for active glaucoma management. Your doctor should tell you specifically how often you need to be seen and why.
What happens if I miss one appointment?
Missing a single appointment is not catastrophic, but rebook immediately. Inform your doctor’s office so your record reflects the gap. If you missed because your disease felt stable, use that reasoning as a reminder of why the disease is dangerous. Glaucoma that feels stable is precisely the glaucoma most likely to be progressing undetected.
My pressure has been normal for two years. Do I still need follow-up?
Yes. Normal pressure does not confirm stability of the optic nerve or visual field. Pressure is one input into glaucoma management, not the only one. Structural and functional monitoring must continue regardless of pressure readings. Normal-tension glaucoma, in which the optic nerve is damaged at statistically normal pressures, makes this point clearly.
Can I do any monitoring at home between visits?
You can monitor for acute angle-closure symptoms, which are dramatic and unmistakeable. For open-angle glaucoma, no reliable home monitoring exists for progression detection. Some research-grade apps are in development but are not yet validated for clinical use. Home monitoring does not replace clinic visits.
My glaucoma has been stable for five years. Can I reduce my follow-up frequency?
Discuss this with your doctor based on your specific risk profile. Long-standing stability is a positive sign. It does not mean the disease has resolved. Optic nerve reserve decreases with age, meaning that the same rate of progression becomes more clinically significant as you get older. Reducing follow-up frequency in stable glaucoma is a clinical decision, not a patient decision.
About the Author
This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. She is also the Program Director for Community Outreach & Wellness; and for the Marengo Asia International Institute of Neuro and Spine.
She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.
As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.
1500+ Five Star Patient Reviews Google Business Profile
If you are unable to come to Dr Bhartiya’s clinic: Read more about teleconsultation for glaucoma
Read her research on PubMed | Google Scholar | ResearchGate | ORCID
Leave a review on Google | Upload your reports for a structured review.| www.drshibalbhartiya.com | +91 88826 38735
Related Reading
Get an Online Glaucoma Consult
Visual Field and OCT: Structure & Function Correlation
Risk Stratification in Glaucoma
